CRDF Cardiff Oncology Inc

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences.

Details of the presentations can be found below.

B. Riley Securities Precision Oncology & Radiopharma Conference

Presenter: Mark Erlander, CEO

Format: Panel discussion on “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”’

Date: 02/28/2025

Location: New York City, NY

This event is for in-person participants only. Contact B. Riley for information on attending the conference.

TD Cowen 45th Annual Health Care Conference

Presenter: Mark Erlander, CEO

Format: Company presentation

Date: 03/5/2025

Time: 11:50 AM ET

Location: Boston, MA

Interested parties can register for and access the live webcast for TD Cowen by visiting the “” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit .

Cardiff Oncology Contact:

James Levine

Chief Financial Officer

858-952-7670

Investor Contact:

Kiki Patel, PharmD

Gilmartin Group

332-895-3225

Media Contact:

Michael Lauer

Taft Communications

732-233-4881





EN
24/02/2025

Underlying

CRDFCardiff Oncology Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cardiff Oncology Inc

 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology Announces Positive Data from Investigator-Initiated T...

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 – Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and objective responses were observed only at the highest dose of onvansertib – – The combination was well-tolerated and demonstrated a safe and manageable toxici...

June 2, 2025 1 EN
 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology Reports First Quarter 2025 Results and Provides Busin...

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Car...

May 8, 2025 1 EN
 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC f...

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043 SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the United States Patent and Trademark Office (USPTO) has issued to Cardiff Oncology U.S. patent No. 1...

April 23, 2025 1 EN
 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 56...

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq...

April 15, 2025 1 EN
 PRESS RELEASE
Free
CRDF Cardiff Oncolog...

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-00...

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced completion of patie...

April 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch